Drug profile · INN
pimozide
ORAP
pimozide (ORAP) is a dopamine receptor antagonist. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — pimozide
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 1
- Programs
- 5
- Data quality
- 0.89
Quick answer
pimozide (ORAP) is a dopamine receptor antagonist. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Dopamine receptor antagonist
Primary target: Dopamine receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is pimozide?
pimozide (ORAP) is a dopamine receptor antagonist. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for pimozide?
ORAP is a marketed brand name for pimozide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of pimozide?
pimozide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.